DURGA-1

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Near Add Your Location

Sorting 33 by

Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Holden Comprehensive Cancer Center - University of Iowa
University of Iowa Hospitals and Clinics
Iowa City, IA
  • Accepting patients
The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.